Profile data is unavailable for this security.
About the company
Veracyte, Inc. is a genomic diagnostics company. The Company, through its scientific platform, which utilizes ribonucleic acid (RNA), whole-transcriptome sequencing combined with machine learning, produces genomic tests. It provides various genomic tests, including Afirma Genomic Sequencing Classifier (GSC), Percepta Bronchial Genomic Classifier, Envisia Genomic Classifier and Afirma Xpression Atlas. It provides GSC tests for thyroid cancer. It provides Percepta Bronchial Genomic Classifier tests for lung cancer. It provides Envisia Genomic Classifier tests for idiopathic pulmonary fibrosis (IPF). Its Afirma Xpression Atlas provides information on gene alterations associated with thyroid cancer, enabling physicians to tailor surgical and treatment decisions at time of diagnosis.
- Revenue in USD (TTM)117.48m
- Net income in USD-34.91m
- LocationVeracyte Inc6000 Shoreline Ct Ste 300SOUTH SAN FRANCISCO 94080-7606United StatesUSA
- Phone+1 (650) 243-6300
- Fax+1 (650) 243-6301
Mergers & acquisitions
|Acquired company||Deal status||Date||Date /|
|VCYT:NMQ since |
|Decipher Biosciences Inc||Deal completed||03 Feb 2021||03 Feb 2021Deal completed||-31.80%||600.00m|